[ad_1]
Family First, which provides employers and health plans with a technology platform to support the mental health and wellbeing of caregivers, secured $11 million in Series A funding.
RPM Ventures and Eos Venture Partners led the round with participation from Stephen Fromm and Wormhole Capital.
“Family First has a holistic and expert approach to solving caregiving issues,” Jonathan Kalman, founding partner of Eos Venture Partners, said in a statement. “And Family First’s leadership has the proven expertise and track record of scaling this kind of expert solution.”
Mental health start-up Uprising announced that it raised $10.7 million in Series A funding, bringing its total raise to $22 million.
New investor Ballast Point Ventures led the round with participation from Front Porch Ventures, Kapor Capital and existing investor B Capital.
The company will use the funds to expand its reach.
“We have long been interested in investing in the behavioral health segment of the healthcare industry, especially as we have seen access to mental health services become even more difficult during the pandemic,” Matt Rice, partner at Ballast Point Ventures, said in a statement. “We are inspired by UpLift’s team care approach, which combines therapy and psychiatry, and we look forward to supporting Kyle Talcott and his impressive team in their mission to improve access to affordable care that patients can trust.”
CathVision, a medical technology company specializing in electrophysiology solutions for clinical decision-making, has secured $9 million in funding, bringing its total raise to $30 million.
The Denmark-based company will use the funds to drive adoption of its ECGenius system, which consists of EP recording technology, and the development of Cardialytics, its AI-based analytics offering.
The money will also support its development of AI-powered analytics modules to provide providers with data during cardiac ablation procedures and help expand its sales team and presence in the United States.
“Despite challenging times in financial markets, CathVision remains a confident investment for stakeholders as we reach critical milestones that validate the need for our technology, revenue generation through successful commercialization, and our commitment to continued R&D,” CathVision CEO Mads Matthiesen said in a statement. “This round of investment will support accelerating commercial adoption through 2024 as we position CathVision to have a meaningful impact on how we in the United States help physicians more effectively treat cardiac arrhythmias.
[ad_2]
Source link